Huntington’s Disease

Update on huntingtin-lowering strategies under investigation for Huntington’s disease 4:14
Update on huntingtin-lowering strategies under investigation for Huntington’s disease
Ann Morgan et al. • 16 Sep 2022
The impact of wild-type HTT suppression on brain function 0:50
The impact of wild-type HTT suppression on brain function
Ann Morgan et al. • 16 Sep 2022
Improving CNS delivery and distribution of Huntington’s disease therapies 2:13
Improving CNS delivery and distribution of Huntington’s disease therapies
Ann Morgan et al. • 16 Sep 2022
ASOs as therapeutic strategies in movement disorders 2:12
ASOs as therapeutic strategies in movement disorders
Tiago Outeiro • 17 Sep 2022
PTC518: oral splicing modifier under investigation for the treatment of Huntington’s disease 5:08
PTC518: oral splicing modifier under investigation for the treatment of Huntington’s disease
Amy-Lee Bredlau et al. • 16 Sep 2022
Phase II PIOVT-HD trial of PTC518 in early Huntington’s disease 3:35
Phase II PIOVT-HD trial of PTC518 in early Huntington’s disease
Amy-Lee Bredlau et al. • 16 Sep 2022
Monitoring children at risk for juvenile Huntington’s disease 1:09
Monitoring children at risk for juvenile Huntington’s disease
Ferdinando Squitieri • 3 Oct 2022
Improving data collection in Juvenile Huntington’s disease 1:12
Improving data collection in Juvenile Huntington’s disease
Ferdinando Squitieri • 3 Oct 2022
Pridopidine application beyond Huntington’s disease 3:03
Pridopidine application beyond Huntington’s disease
Michael Hayden • 27 Sep 2022
PROOF-HD: Phase III trial of oral S1R agonist pridopidine for the treatment of Huntington’s disease 5:38
PROOF-HD: Phase III trial of oral S1R agonist pridopidine for the treatment of Huntington’s disease
Michael Hayden • 27 Sep 2022
Huntingtin function in health and disease: axonal transport 4:57
Huntingtin function in health and disease: axonal transport
Frederic Saudou • 20 Sep 2022
Symptoms of juvenile onset Huntington’s disease 3:35
Symptoms of juvenile onset Huntington’s disease
Ferdinando Squitieri • 3 Oct 2022
Advancing mHTT as a biomarker in Huntington’s disease 2:06
Advancing mHTT as a biomarker in Huntington’s disease
Lauren Byrne • 23 Sep 2022
Tackling cognitive impairment in Huntington’s disease: a significant unmet need 2:05
Tackling cognitive impairment in Huntington’s disease: a significant unmet need
Aaron Koenig • 22 Sep 2022
Strategies to improve ASOs in Huntington’s disease 1:56
Strategies to improve ASOs in Huntington’s disease
Patrick Weydt • 23 Sep 2022
Huntingtin lowering: what level of wildtype protein knockdown is safe? 2:21
Huntingtin lowering: what level of wildtype protein knockdown is safe?
Michael Hayden • 27 Sep 2022
The content of VJNeurology is intended for healthcare professionals